Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Immunol. 2012 Dec 7;190(1):469–478. doi: 10.4049/jimmunol.1201209

FIGURE 5.

FIGURE 5

Regression of dermal melanoma by cps treatment stimulates vitiligo and supports systemic and memory antitumor immune responses. (A) Picture of mice exhibiting vitiligo after elimination of primary dermal B16F10 melanoma by cps treatment. (B) Graph of % of mice that developed vitiligo, 22 of 29 (76%) of cps treated mice got detectable vitiligo (among wild type mice with no other manipulation). (C) Treatment strategy for rechallenge during primary tumor treatment. (D) Growth curve of B16 intradermal rechallenge, same and opposite flank. (E) Survival curves for flank rechallenges. (F) dermal rechallenge on day 40 (left) or day 120 (right) after establishment of primary tumor. cps groups had the primary tumor regressed by cps, PBS-treated groups had the primary tumor surgically resected on day 13. Error bars are SEM; P values: * < 0.05, ** < 0.01, *** < 0.001. n= minimum of 5, data are representative of 2 independent experiments..